Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.

Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA29 Aug 2012Cited by 8 (Europe PMC)

PMID22930240PMCIDPMC4890154DOI10.1007/s00198-012-2098-3PepBankPUB-22930240

Source link PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, PTH increased lumbar spine BMD 6.8% above baseline over 24 months (p<0.05).
In plain wordsIn postmenopausal osteoporosis, PTH increased spine bone density 6.8% above baseline over 24 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase above baseline
6.8%
PTH(1-84) over 24 months
Source sentences
Summary
PTH(1-84) treatment over 24 months increased BMD at the lumbar spine by 6.8% above baseline (p<0.05).The total corresponding BMD increases at the hip and femoral neck were 1.1 and 2.2% above baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024001
02HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, PTH increased hip BMD 1.1% above baseline over 24 months.
In plain wordsIn postmenopausal osteoporosis, PTH increased hip bone density 1.1% above baseline over 24 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseHip BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Total hip BMD increase above baseline
1.1%
PTH(1-84) over 24 months
Source sentences
Summary
PTH(1-84) treatment over 24 months increased BMD at the lumbar spine by 6.8% above baseline (p<0.05).The total corresponding BMD increases at the hip and femoral neck were 1.1 and 2.2% above baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024002
03HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, PTH increased femoral neck BMD 2.2% above baseline over 24 months.
In plain wordsIn postmenopausal osteoporosis, PTH increased femoral neck bone density 2.2% above baseline over 24 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseFemoral neck BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Femoral neck BMD increase above baseline
2.2%
PTH(1-84) over 24 months
Source sentences
Summary
PTH(1-84) treatment over 24 months increased BMD at the lumbar spine by 6.8% above baseline (p<0.05).The total corresponding BMD increases at the hip and femoral neck were 1.1 and 2.2% above baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024003
04HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, BSAP peaked after 6 months of PTH and remained above baseline at 24 months despite subsequent decline.
In plain wordsIn postmenopausal osteoporosis, BSAP peaked after 6 months of PTH and remained above baseline at 24 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseBSAP trajectory
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Markers of bone turnover (BSAP and NTx) peaked 6 months after starting PTH(1-84) treatment and declined slowly but remained above baseline at 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024006
05HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, NTx peaked after 6 months of PTH and remained above baseline at 24 months despite subsequent decline.
In plain wordsIn postmenopausal osteoporosis, NTx peaked after 6 months of PTH and remained above baseline at 24 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseNTx trajectory
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Markers of bone turnover (BSAP and NTx) peaked 6 months after starting PTH(1-84) treatment and declined slowly but remained above baseline at 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024007
06HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, BSAP returned near baseline by month 30 after PTH discontinuation at month 24.
In plain wordsIn postmenopausal osteoporosis, BSAP returned near baseline by month 30 after PTH discontinuation at month 24.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseBSAP after discontinuation
Study
n: not reported in source
Comparator
Values at discontinuation
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
After discontinuation of PTH(1-84) treatment (at 24 months), bone turnover markers returned to near baseline levels by 30 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Markers of bone turnover (BSAP and NTx) peaked 6 months after starting PTH(1-84) treatment and declined slowly but remained above baseline at 24 months.
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024008
07HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, NTx returned near baseline by month 30 after PTH discontinuation at month 24.
In plain wordsIn postmenopausal osteoporosis, NTx returned near baseline by month 30 after PTH discontinuation at month 24.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseNTx after discontinuation
Study
n: not reported in source
Comparator
Values at discontinuation
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
After discontinuation of PTH(1-84) treatment (at 24 months), bone turnover markers returned to near baseline levels by 30 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Markers of bone turnover (BSAP and NTx) peaked 6 months after starting PTH(1-84) treatment and declined slowly but remained above baseline at 24 months.
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024010
08HumanObservational studyEfficacy outcome
In postmenopausal osteoporosis, PTH adherence ≥80% was linked to larger spine BMD gains: 8.3% versus 4.9% with poor adherence.
In plain wordsIn postmenopausal osteoporosis, better PTH adherence was linked to larger spine bone density gains than poor adherence.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseAdherence association with spine BMD gains
Study
n: not reported in source
Comparator
Poorly adherent PTH recipients
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Spine BMD increase, adherent (>=80%)
8.3%
adherent patients
Spine BMD increase, poorly adherent
4.9%
poorly adherent patients
Source sentences
Summary
Larger increases in spine BMD were observed in participants with ≥80% adherence to daily injections of PTH(1-84) (8.3% in adherent vs 4.9% in poorly adherent patients).
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024004
09HumanObservational studyEfficacy outcome
In postmenopausal osteoporosis, adherent PTH recipients had hip BMD gains of 1.7% versus 0.6% in poorly adherent recipients.
In plain wordsIn postmenopausal osteoporosis, better PTH adherence was linked to larger hip bone density gains than poor adherence.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseAdherence association with hip BMD gains
Study
n: not reported in source
Comparator
Poorly adherent PTH recipients
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Total hip BMD gain, adherent
1.7%
adherent participants
Total hip BMD gain, poorly adherent
0.6%
poorly adherent participants
Source sentences
Summary
Total hip BMD gains were 1.7% in adherent vs 0.6% in poorly adherent participants.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024005
10HumanObservational studyEfficacy outcome
In postmenopausal osteoporosis, adherent PTH recipients sustained significantly fewer fractures than poorly adherent recipients.
In plain wordsIn postmenopausal osteoporosis, better PTH adherence was linked to fewer fractures than poor adherence.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseAdherence association with fractures
Study
n: not reported in source
Comparator
Poorly adherent PTH recipients
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
The adherent group sustained significantly fewer fractures than the poorly adherent group.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment.
Report a problemFND-2293024009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms